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It is not always possible to administer antituberculosis pharmacotherapy orally for reasons that may 
be a direct consequence of tuberculosis itself. To our knowledge, no published literature is available 
regarding antituberculosis drug absorption via feeding tube. We present the case of a patient with 
tuberculosis meningitis who required medication administration via percutaneous endoscopic 
jejunostomy (PEJ) tube. Blood samples were collected during the continuation phase of 
antituberculosis therapy, immediately before dose administration, and then at 1, 2, 4, and 6 hours 
after dose administration for quantification of serum rifampin concentrations. Assaying these 
concentrations by high-pressure liquid chromatography demonstrated a peak serum rifampin level 
(Cmax) of 18 lg/ml and total rifampin exposure (area under the curve from 0–6 hours [AUC0–6]) of 
50.1 lg/ml. These are high compared with rifampin Cmax and AUC0–6 values reported in patients 
after oral rifampin administration; Cmax tends to range between 4.0–10.5 lg/ml and AUC0–6 7.0–
52.9 lg/ml after oral administration of 600 mg at steady state. Based on our patient’s results, 
therefore, rifampin administered by PEJ tube appears to be well absorbed, with preservation of 
adequate Cmax and AUC values. It is worth noting that this was in the context of drug administration 
in the fasted state. In the absence of any published evidence of adequate absorption via jejunal 
feeding tube in the nonfasted state, it would seem prudent to ensure that patients are fasted when 
rifampin is administered via PEJ tube, just as patients are when oral rifampin is administered. This 
report represents the first documented evidence, to our knowledge, of adequate rifampin 
absorption when administered via PEJ tube and provides important reassurance for health care 
providers, patients, and families facing similar clinical scenarios. 
 
Introduction 
Rifampin is an important part of the first-line treatment regimen for tuberculosis, driving sterilizing 
activity.1, 2 Its bactericidal effect on Mycobacterium tuberculosis is intracellular and concentration 
dependent, with microbial killing linked to the area under the curve to minimum inhibitory 
concentration (AUC:MIC) ratio and suppression of resistance linked to the free-drug peak 
concentration (Cmax):MIC ratio.3, 4 Rifampin is rapidly and almost completely absorbed after oral 
administration on an empty stomach, with Cmax achieved ~2 hours after ingestion.5–7 Rifampin 
induces its own metabolism via increased prehepatic and hepatic clearance,8 and the induced 
steady state is achieved after ~40 days of treatment.9 We performed a search for relevant literature 
regarding administration of antituberculosis pharmacotherapy via percutaneous endoscopic 
jejunostomy (PEJ) tube, and no published evidence or guidance was found. Thus we conducted a 
pharmacokinetic investigation to assess whether absorption via this route would be adequate, using 
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serum samples from a patient with tuberculosis meningitis who required rifampin administration via 
PEJ tube. 
 
Case Report 
A 61-year-old man was admitted to our regional tropical and infectious diseases unit with vomiting, 
back pain, and urinary retention on a background of fever and weight loss. He became confused and 
developed impaired consciousness, and was diagnosed with tuberculosis meningitis on a clinical and 
radiologic basis. Neurologic impairment included dysphagia, and a PEJ tube was placed for 
nutritional support and medication administration. Local discussions between the medical staff and 
pharmacy staff raised concerns that jejunal administration may lead to impaired drug absorption, 
raising the possibility of treatment failure and the development of drug resistance. The patient was 8 
weeks into the continuation phase of his daily-dosed therapy and thus had reached the fully induced 
metabolic steady state. Over 8 hours after and 6 hours before any food or enteral feeding solution 
was given, and 24 hours after the previous dose, 600 mg rifampin solution (100 mg/5 ml; Rifadin; 
Sanofi, Guildford, UK) and 300 mg isoniazid oral solution were administered via PEJ tube. Serum 
samples were collected immediately before dose administration and at 1, 2, 4, and 6 hours after 
dose administration. Rifampin concentrations were assayed by high-pressure liquid chromatography 
at the Antimicrobial Reference Laboratory (Bristol, UK) (Table 1). These values equated to a Cmax of 
18 lg/ml and area under the curve from 0–6 hours (AUC0-6) of 50.1 lg/ml. 
 
Discussion 
The serum rifampin levels reached in this patient were high compared with levels described in the 
published literature after oral administration. Average Cmax values reported in studies assessing 
rifampin pharmacokinetics after oral administration of 600 mg at steady state generally ranged from 
4.0–10.5 lg/ml.10–17 Importantly, we were able to calculate an AUC to enable an estimation of 
bactericidal activity. The total drug exposure achieved in our patient (50.1 lg/ml) falls at the very 
upper end of the range reported by other investigators after oral administration of the same dose: a 
median AUC0-6 of 24.0 lg/ml (range 7–52.4 lg/ml) and 21.7 lg/ml (range 7.1– 52.9 lg/ml) in human 
immunodeficiency virus (HIV)-positive and HIV-negative patients, respectively.17 After a similar dose 
of 9.6 mg/kg, another study reported a mean AUC0-6 of 16.52 lg/ml (SD 8.84 lg/ml) in HIV-positive 
patients and 17.94 lg/ml (SD 10.36 lg/ml) in HIV-negative patients.18 A multitude of factors need to 
be accounted for when planning to deliver drugs by jejunal feeding tubes. Product alterations 
necessary to allow tube delivery may interfere with product stability, compatibility with concomitant 
medications, and tolerability, as well as pharmacokinetic parameters.19 These considerations are 
drug specific. The accepted practice of administering rifampin on an empty stomach is supported by 
evidence that ingestion of food with rifampin reduces Cmax by more than a third.2, 20 Because 
jejunal pH is significantly higher than gastric pH,21 a concern in our unit was that relative alkalinity 
would impair rifampin absorption in our patient. This was not the case; indeed, in patients taking 
rifampin orally, concomitant antacid administration has no effect on serum rifampin levels.2, 20 
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Some evidence exists that many viable targets may be available for rifampin absorption in the 
gastrointestinal tract. Subtotal or total gastrectomies, celiac disease, and diverticulosis of the small 
bowel do not result in differences in AUC compared with those attained in patients with healthy 
gastrointestinal tracts.22 A study conducted in India demonstrated Cmax and AUC values that were, 
in fact, slightly higher in 12 patients with gastrointestinal tuberculosis affecting the ileum, cecum, 
and/or duodenum than in 18 comparable patients with pulmonary tuberculosis without evidence of 
gastrointestinal involvement.23 Rifampin is zwitterionic with an acidic pKa of 1.7 and an alkaline pKa 
of 7.9.24 Its permeability is high in the relatively alkaline environments of the duodenum and colon 
in comparison with the acidic stomach, and solubility is moderate to high throughout.25 It is also 
known to be highly lipophilic. These qualities mean that it is perhaps not surprising that absorption 
can occur at many gastrointestinal sites. 
 
Conclusion 
Based on our case study, it appears that rifampin administered by jejunal tube is well absorbed, with 
preservation of adequate Cmax and AUC values. It is worth noting that this was in the context of 
drug administration in the fasted state. In the absence of any published evidence of adequate 
absorption via jejunal feeding tube in the non-fasted state, it would seem prudent to ensure that 
patients are fasted when rifampin is administered via PEJ tube, just as patients are when oral 
rifampin is administered. 
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Table 1: Serum Rifampin Concentrations after PEJ Tube Administration 
Time point Rifampin concentration (μg/mL) 
Before dosing < 0.3 
1 hour after dosing 18.0 
2 hours after dosing 11.0 
4 hours after dosing 6.1 
6 hours after dosing 3.4 
PEJ = percutaneous endoscopic jejunostomy. 
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